
    
      The Infinity-Swedeheart trial is a prospective, multicenter, single-blind, randomized
      registry-based clinical trial. Eligible patients will be randomized 1:1 (DynamX Bioadaptor :
      Resolute Onyx). 2400 Patients will be randomized in Sweden. Patients will be followed at 30
      days and 1 year by phone, and at 6 months and 2 to 5 years through clinical and diagnostic
      registries.
    
  